Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

To sequence or not to sequence?

B Gazzard, G Moyle

    Expert Opinion on Investigational Drugs
    |February 1, 1997
    PubMed
    Summary
    This summary is machine-generated.

    Highly effective antiretroviral combinations significantly improve prognosis for HIV patients by suppressing viral load. However, the long-term impact and potential for viral persistence require further investigation and clinical trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The EuroSIDA study: 25 years of scientific achievements.

    HIV medicine·2019
    Same author

    Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson's disease.

    NeuroRehabilitation·2019
    Same author

    Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

    Journal of neurovirology·2018
    Same author

    CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

    Journal of neurovirology·2017
    Same author

    Amprenavir : A Viewpoint by Graeme Moyle.

    Drugs·2016
    Same author

    Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

    International journal of STD & AIDS·2016
    Same journal

    Advancements in longevity pharmacology research - are we finally seeing clinical progression?

    Expert opinion on investigational drugs·2026
    Same journal

    Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

    Expert opinion on investigational drugs·2026
    Same journal

    Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

    Expert opinion on investigational drugs·2026
    Same journal

    Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

    Expert opinion on investigational drugs·2026
    Same journal

    Odronextamab: a bispecific antibody for follicular lymphoma.

    Expert opinion on investigational drugs·2026
    Same journal

    Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

    Expert opinion on investigational drugs·2026
    See all related articles

    Area of Science:

    • Virology
    • Immunology
    • Pharmacology

    Background:

    • Combination antiretroviral therapy (ART) is superior to monotherapy for treating HIV infection.
    • Effective ART regimens achieve profound reductions in plasma HIV viral load, often to undetectable levels.
    • Reduced viral replication delays the emergence of drug-resistant HIV mutants, a primary cause of treatment failure.

    Discussion:

    • Highly effective ART combinations are expected to delay clinical progression and improve the long-term prognosis for individuals with HIV.
    • Mathematical modeling suggests potential for therapy cessation after prolonged viral suppression, though viral persistence in sanctuary sites (e.g., CNS, genital tract) remains a concern.
    • Achieving an undetectable viral load with potent initial combination therapy is crucial for a prolonged therapeutic effect, especially with good patient compliance.

    Related Experiment Videos

    Key Insights:

    • The principal reason for therapeutic failure in HIV treatment is the selection of viral mutants resistant to drugs.
    • Some researchers hypothesize that sustained undetectable viral loads may allow for treatment interruption, while others caution against this due to potential viral persistence.
    • The debate continues on whether to prioritize the strongest initial combination therapy or to consider drug sequencing to mitigate future resistance.

    Outlook:

    • Further controlled clinical trials are urgently needed to evaluate the hypotheses regarding treatment interruption and optimal drug sequencing strategies.
    • Understanding viral dynamics in cellular reservoirs is critical for long-term HIV management.
    • The development of novel therapeutic strategies may be informed by ongoing research into viral persistence and resistance mechanisms.